Skip to main content
. 2020 May 11;13(6):100775. doi: 10.1016/j.tranon.2020.100775

Figure 3.

Figure 3

AZA differentially inhibits Wnt signaling transduction pathway and angiogenesis-related markers in vitro. (A) Expression of Wnt-3, Wnt-4, GSK-4, and beta-catenin in 231 and 231Br cells after AZA treatment for 72 hours measured by Western blotting assay. GAPDH was used as the loading control. The blots shown are a presentation of two independent experiments. (B) Expression of VEGF receptor 2 and hypoxia-inducible factor-1 alpha in 231 and 231Br cells after AZA treatment for 72 hours measured by Western blotting assay. GAPDH was used as the loading control. The blots shown are a presentation of two independent experiments. (C) VEGF mRNA level in 231 and 231Br cells after AZA treatment for 72 hours measured by real-time PCR. All error bars represent SD, N = 3 technical replicates, representative of two independent experiments. *P < .05, **P < .01, ***P < .001. (D) The amount of VEGF released into the cell culture medium of 231 and 231Br cells after 72 hours of AZA treatment measured by ELISA. All error bars represent SD, N = 3 technical replicates, representative of two independent experiments. *P < .05, **P < .01, ***P < .001.